Long-Term Safety of Viagra (Sildenafil)
Long-term use of sildenafil (Viagra) is generally safe with mild to moderate adverse effects, though serious cardiovascular events and vision loss remain rare but important risks that require patient counseling and appropriate screening before initiation.
Overall Safety Profile
Based on high-quality guideline evidence, PDE-5 inhibitors like sildenafil are relatively well-tolerated with serious adverse events occurring in less than 2% of patients, with no significant difference from placebo 1. The most common side effects are:
- Headache, flushing, rhinitis, and dyspepsia (most frequent)
- Visual disturbances, myalgia, nausea, diarrhea, dizziness (less common) 1
Long-term extension studies demonstrate that 90% of patients completed 1-year treatment with only 1% withdrawing due to lack of efficacy, confirming sustained tolerability 2. Data from patients exposed to sildenafil for up to 4.5 years show consistent safety profiles 3.
Cardiovascular Risks: The Critical Consideration
Absolute Contraindication
Concurrent use of nitrates (regular or intermittent) is an absolute contraindication 1, 4. The combination can cause severe hypotension.
Serious Cardiovascular Events
Post-marketing surveillance has identified serious events including myocardial infarction, sudden cardiac death, ventricular arrhythmia, stroke, and hemorrhages 4. However, most patients experiencing these events had pre-existing cardiovascular risk factors 4.
High-Risk Populations Requiring Caution
Sildenafil should be prescribed cautiously (or avoided) in 4:
- Patients within 6 months of myocardial infarction, stroke, or life-threatening arrhythmia
- Resting hypotension (BP <90/50) or hypertension (BP >170/110)
- Cardiac failure or unstable angina
- Left ventricular outflow obstruction (aortic stenosis, hypertrophic cardiomyopathy)
- Severely impaired autonomic blood pressure control
Emerging Cardiovascular Benefits
Interestingly, recent 2024 data suggests potential cardiovascular protective effects, with tadalafil and sildenafil associated with reduced risks of all-cause mortality (RR 0.76 for sildenafil), myocardial infarction (0.83), stroke (0.78), and venous thromboembolism (0.80) over 3 years 5. This represents a paradigm shift, though these benefits appear in appropriately selected patients without contraindications.
Vision-Related Risks: Rare but Serious
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy)
Evidence is insufficient to definitively link PDE-5 inhibitors to increased NAION risk 1. Large veteran studies showed no increased risk for NAION (RR 1.02), though "possible NAION" had a modest association (RR 1.34, absolute risk 2.4 cases per 10,000 men per year) 1.
Post-marketing reports of sudden vision loss have occurred, including permanent vision loss 4. Risk factors include:
- Age >50 years
- "Crowded disc" (low cup-to-disc ratio)
- Diabetes, hypertension, coronary artery disease
- Hyperlipidemia, smoking 4
Patients with prior NAION in one eye face increased risk and require careful counseling 4.
Other Visual Effects
Common visual disturbances (blurred vision, color tinge) are typically mild and transient 6. Animal studies suggest chronic high-dose exposure may cause retinal toxicity, though human relevance at therapeutic doses remains unclear 7.
Perioperative Risk
Sildenafil should be discontinued at least one week before elective surgery to reduce the theoretical risk of perioperative vision loss, as anesthesia and surgery independently carry small risks of visual complications 8.
Other Long-Term Risks
Priapism and Prolonged Erection
Priapism occurs in approximately 1% of patients 9. Prolonged erections >4 hours require immediate medical attention to prevent permanent penile tissue damage and loss of potency 4.
Hearing Loss
Sudden hearing loss has been reported post-marketing, often with tinnitus and dizziness 4. Patients should stop the medication and seek prompt evaluation if this occurs.
Unexpected Adverse Events
Recent pharmacovigilance data identified signals for malignant melanoma, pulmonary hypertension, and acquired hemophilia 6. While causality is unproven, these warrant further investigation.
Clinical Algorithm for Safe Long-Term Use
Before initiating sildenafil:
- Screen for nitrate use (absolute contraindication)
- Assess cardiovascular status and recent events (<6 months)
- Measure blood pressure
- Identify NAION risk factors (prior episode, crowded disc, vascular risk factors)
- Document baseline hearing and vision concerns
During long-term treatment:
- Counsel patients to stop medication and seek immediate care for:
- Erections lasting >4 hours
- Sudden vision or hearing loss
- Chest pain or cardiovascular symptoms during sexual activity
- Start with lowest effective dose (25-50 mg)
- Avoid in patients on alpha-blockers until stable on alpha-blocker therapy 4
- Consider dose reduction with CYP3A4 inhibitors (ritonavir requires substantial dose reduction) 4
The evidence supports continued use when:
- No serious adverse events occur
- Cardiovascular status remains stable
- Patient derives quality-of-life benefit
Key Pitfalls to Avoid
- Failing to ask about nitrate use (including recreational "poppers")
- Ignoring recent cardiovascular events (<6 months is high-risk period)
- Not counseling about priapism management (immediate medical attention for >4 hours)
- Dismissing visual or hearing symptoms as benign
- Continuing perioperatively without appropriate washout period
The evidence demonstrates that for appropriately selected patients without contraindications, long-term sildenafil use has an acceptable safety profile with predominantly mild, manageable adverse effects 1, 3, 2. The key is rigorous initial screening and ongoing patient education about warning signs requiring immediate medical attention.